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Transactive response DNA-binding protein 43 (TDP-
43) is the pathological signature protein in several
neurodegenerative disorders, including the majority
of frontotemporal lobar degeneration cases (FTLD-
TDP), motor neuron disease, and amyotrophic lateral
sclerosis. Pathological TDP-43 is mislocalized from its
nuclear location to the cytoplasm, where it accumu-
lates and is proteolytically cleaved to form C-terminal
fragments. Although the 25-kDa C-terminal fragment
of TDP-43 (TDP-25) accumulates in affected brain re-
gions, its role in the disease pathogenesis remains
elusive. To address this problem, we have generated a
novel transgenic mouse that selectively expresses
TDP-25 in neurons. We show that transgenic mice
expressing TDP-25 develop cognitive deficits associ-
ated with the build-up of soluble TDP-25. These cog-
nitive deficits are independent of TDP-43–positive in-
clusions and occur without overt neurodegeneration.
Additionally, we show that the expression of TDP-25
is sufficient to alter the processing of endogenous
full-length TDP-43. These studies represent the first in
vivo demonstration of a pathological role for TDP-25
and strongly suggest that the onset of cognitive defi-
cits in TDP-43 proteinopathies is independent of
TDP-43 inclusions. These data provide a framework for
understanding the molecular mechanisms underlying
the onset of cognitive deficits in FTLD-TDP and other
TDP-43 proteinopathies; thus, the TDP-25 transgenic
mice represent a unique tool to reach this goal. (Am J
Pathol 2012, 180:293–302; DOI: 10.1016/j.ajpath.2011.09.022)
Transactive response DNA-binding protein 43 (TDP-43)
is a conserved and ubiquitously expressed DNA-RNA
binding protein. It is encoded by the TARDBP gene onchromosome 1, which is made of six exons that can be
alternatively spliced to yield 11 different isoforms, with the
mRNA encoding TDP-43 being the major species.1 Func-
tionally, TDP-43 appears to be involved in exon skipping
and alternative splicing.2,3 Structural studies have con-
firmed the presence of two RNA recognition motifs
(RRM1 and RRM2) and a glycine-rich C-terminal tail,
which is thought to mediate protein–protein interac-
tions.4 However, TDP-43 function appears not to be
confined to the nucleus. Indeed, recent evidence indi-
cates that TDP-43 may play a role in synaptic plasticity
by regulating local translation in dendritic spines upon
neuronal stimuli.5
Frontotemporal lobar degeneration (FTLD) is a hetero-
geneous disorder that represents the second most com-
mon form of dementia in people under the age of 65
years.6 The majority of FTLD cases are characterized by
the accumulation of TDP-43 and are referred to as FTLD-
TDP.7 Additionally, mutations in the TARDBP gene are
linked to amyotrophic lateral sclerosis (ALS),8 a neurode-
generative disorder with clinical and neuropathological
features overlapping with FTLD-TDP.9 Pathological
TDP-43 is mislocalized from its nuclear location to the
cytoplasm, where it accumulates and is proteolytically
cleaved to form C-terminal fragments, mainly of 25 and
35 kDa.7 Notably, the accumulation of a 25-kDa C-termi-
nal fragment of TDP-43 (TDP-25) is an invariable feature
of FTLD-TDP. Even though it has been proposed that
TDP-25 may play a role in neurodegeneration,7,10–15 little
is known about the role of this peptide in disease patho-
genesis. Animal models overexpressing TDP-43 recapit-
ulate several key features of FTLD-TDP and ALS16–22;
however, these models do not elucidate the role of
TDP-25 in TDP-43 proteinopathies. Toward this end, mul-
tiple laboratories, including ours, have shown that the
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leads to ubiquitinated and abnormally phosphorylated
cytoplasmic inclusions in a variety of cell lines.10,11,13–15
However, it remains to be established whether TDP-25
plays a role in the pathogenesis of FTLD-TDP in vivo. To
address this critical aspect in FTLD-TDP, we report here the
generation of a novel transgenic mouse that selectively ex-
presses TDP-25 in neurons, thereby providing direct in vivo
evidence for a role of TDP-25 in the onset of cognitive
deficits associated with TDP-43 proteinopathies.
Materials and Methods
Generation of the Transgenic Mice
To clone TDP-25 in the Thy1.2 expression cassette,23 we
used a homologous recombination-based approach
(InFusion system; BD Biosciences, Franklin Lakes, NJ).
TDP-25 was amplified by PCR using full-length human
TDP-43 as a template and a proof-checking DNA poly-
merase with two primers that included 16 bp of homology
to the site of insertion within the Thy1.2 multiple cloning
site (forward primer 5=-TCTCGACGGCGTCGACCAC-
CATGGATGTGATGGATGTCAAG-3=; reverse primer 5=-
GAGGAAGGACCTCGAGCTAGTGATTCATTCCCCAGC-
CAG-3=). The forward primer also included a Kozak
consensus site (CCACC) and an ATG starting codon. To
prepare the expression cassette, we linearized the empty
Thy1.2 plasmid by restriction digestion using SalI and
XhoI enzymes. Both the PCR product and the linearized
plasmid were subsequently purified by gel extraction be-
fore the recombination reaction. To elicit recombination
between the Thy1.2 plasmid and the PCR insert, we com-
bined 100 ng of linearized Thy1.2 plasmid and 50 ng of
the PCR product within 10 L of water; the mix was
added to the InFusion Dry-Down Mix (BD Biosciences)
and incubated at room temperature for 30 minutes. The
InFusion mix contains a proprietary recombinase enzyme
that catalyzes the specific recombination of two double-
stranded homologous regions of DNA. Given the primer’s
design, this reaction led to a highly accurate and specific
recombination event and insertion of the PCR product
within the Thy1.2 expression cassette. We next screened
via restriction digestion individual colonies obtained from
transforming chemically competent Escherichia coli cells
(DH5) to identify those expressing the Thy1.2-TDP-25
construct. To further confirm the identity of our construct,
the entire transgene of two clones was sequenced, and
its position within the Thy1.2 plasmid was also confirmed.
The Thy1.2-TDP-25 construct was released from the vec-
tor via PvuI-EcoRI digestion and purified using a gel
purification system. For the generation of transgenic
mice, the transgenes were injected into oocytes isolated
from pure C57BL/6 mice by the transgenic mouse facility
at the University of Texas at Austin. Founders, identified
by PCR of DNA extracted from tail biopsies, were back-
crossed to C57BL/6 mice to generate F1s.Real-Time PCR and Determination of Copy
Number
Total RNA was extracted using the RT2 qPCR-Grade RNA
Isolation Kit (SABioscience, Qiagen, Valencia, CA) ac-
cording to the manufacturer’s protocol and quantified
using a Bio Spec-1601 (SHIMADZU, Kyoto, Japan) spec-
trophotometer. One microgram of total RNA was used to
make the cDNA by using RT2 First Strand Kit (SABiosci-
ence) in a total volume of 20 L according to the manu-
facturer’s protocol. After real-time PCR, 1 L of cDNA
was amplified and quantified in 96-well plates using ABI
Prism 7000 sequence detection (Applied Biosystems,
Foster City, CA). For the determination of copy number,
DNA isolated from the B and F lines (n  5/line) was
amplified and quantified in 96-well plates using ABI Prism
7000 sequence detection (Applied Biosystems). The fol-
lowing specific primers were used: 5=-CCCATGTTCT-
GAGATATTTG-3= and 5=-GTAATAACCAAAACCAAGGC-
3=. Notably, the forward primer was complementary to the
promoter region immediately upstream of the TDP-25
sequence. The reverse primer was complementary to the
5=-end region of the TDP-25 region. Using these primers,
we amplified a region unique to the transgene, and no
endogenous bands were amplified. The amplification
conditions consisted of an initial activation step at 95°C
for 10 minutes, and 40 cycles at 95°C for 15 seconds,
55°C for 30 seconds, and 72°C for 30 seconds. The
fluorescence of the accumulated double-stranded prod-
ucts was monitored in real time. The relative DNA levels
were normalized to the reference housekeeping gene
presenilin 1 using the following primers: forward, 5=-CA-
CACGCACACTCTGACATGCACAGGC-3= and reverse,
5=-AGCCAGGAAGATCACGTGTTCCAAGTAC-3=. The
copy number in transgenic mice was determined using a
serial dilution of mouse genomic DNA containing 0 to 10
copies per cell equivalent of the plasmid DNA used to
generate the mice. A standard curve in threshold cycle (Ct)
and copy number was generated in Excel (Microsoft, Red-
mond, WA), and unknowns were determined using the
equation generated during the linear regression analysis.
Behavioral Testing
Open-Field Locomotion
The test was conducted in a clear Plexiglas box (40 
40 cm) and was recorded with a video camera mounted
above the testing box. Mice were handled for 5 days prior
to the beginning of the test. The test consisted of 10
minutes of free exploration. With the EthoVision XT tracking
system (Noldus Information Technology, Leesburg, VA), we
recorded the total distance traveled by the mice and the
time spent in the center and close to the box walls.
Object Recognition
Mice were left free to explore two objects for 5 minutes
in the same arena used for open-field activity. After a
10-minute delay, where the mice were returned to the
home cage, mice were retested in the arena where one of
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percentage of time spent exploring the new object was
measured with EthoVision.
T-Maze
We previously reported a detailed protocol for the T-
maze.24 Briefly, the T-maze consists of a central main
arm with two side arms positioned perpendicular to the
main arm. The central arm is 65 cm long, and the two side
arms are each 30 cm long. The maze width is 13.5 cm.
The walls of the maze are made of black acrylic and are
20 cm tall. At the beginning of each test, mice were
placed in the main stem while one side arm was blocked
by a barrier so that the mice were forced to choose
the other arm. Once a mouse entered the side arm, the
entrance to that arm was blocked, thereby retaining the
mouse within the side arm. Mice were allowed to explore
that arm for 120 seconds, at the end of which time period,
they were placed back in the main arm of the maze with
both side arms open. During this test, mice were free to
choose the arm that they had already explored or the new
arm. Each animal was tested daily for 7 days, and each
day the side arms were alternately blocked. The number
of alternations and the latency to make a choice during
the free trial were recorded.
Rotarod
Each mouse was trained for three consecutive days
(six trials/day) where the speed of the rotor was acceler-
ated from 0 to 15 rpm in 20 seconds and then kept at 15
rpm for 70 additional seconds. Twenty-four hours after
the last training session, the mice were tested in a probe
trial consisting of six consecutive trials on an accelerating
rod (1 rpm/second). The latency to fall was then re-
corded.
Tissue Processing, Immunohistochemistry, and
Western Blot Analysis
After completion of the behavioral tasks, mice were per-
fused with ice-cold PBS, then their brains were extracted
and cut sagitally: one-half of each brain was frozen in dry
ice and used for biochemical analyses, and the other half
was fixed in 4% ice-cold paraformaldehyde for 48 hours
and subsequently sliced for immunohistochemical anal-
ysis, as we previously reported.25 Sections were stained
with an anti-ubiquitin antibody (Sigma-Aldrich, St. Louis,
MO), and with anti–TDP-43 C-terminus 405-414 and anti-
phospho TDP-43 pS409/410-2 (CosmoBio, Tokyo, Japan).
Sequential Biochemical Extraction
Frozen hemibrains were homogenized in 1 mL of low-salt
solution [10 mmol/L Tris (pH 7.5), 5 mmol/L EDTA, 1
mmol/L DTT, 10% sucrose, protease inhibitors] using
power homogenizer, centrifuged at 25,000  g for 30
minutes at 4°C. The supernatant was saved as a low-salt
fraction. The pellet was rehomogenized in 1 mL of high-salt solution (1% Triton X-100, 0.5 mol/L NaCl, protease
inhibitor) and centrifuged at 90,000  g for 1 hour at 4°C.
The supernatant was saved as a high-salt fraction. The
pellet underwent further sequential extraction in sarkosyl
buffer (low-salt  1% sarkosyl  0.5 mol/L NaCl) and in
urea buffer (7 mol/L urea, 2 M thiourea, 4% CHAPS, 30
mmol/L Tris).
Nuclear and Cytosolic Fractionation
Frozen hemibrains were washed in PBS and placed in a
Dounce homogenizer with 2 mL of solution A [10 mmol/L
Hepes (pH 7.9), 10 mmol/L KCL, 0.1 mmol/L EDTA, 0.1
mmol/L EGTA, 1 mmol/L DTT, protease inhibitors]. After
five strokes, we added 0.5% vol/vol of NP40, and the
tissue was further homogenized with five additional
strokes. The solution was then equally divided into four
different tubes and centrifuged 1 minute at 12,000  g.
The supernatant was removed and stored at 80°C as
the cytosolic fraction. The pellet was resuspended in 250
L of Solution C [20 mmol/L Hepes (pH 7.9), 400 mmol/L
NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L DTT,
protease inhibitors], mixed by pipetting and incubated for
15 minutes at 4°C. Subsequently, the tissue was centri-
fuged 5 minutes at 12,000  g. and the supernatant was
stored at 80°C as the nuclear fraction. Western blot
analyses was conducted as previously described.26 The
TDP-43 blots were probed with the anti-TDP TARDBP
polyclonal antibody (ProteinTech Group, Chicago, IL).
Fluoro-Jade Staining and Quantification
Fluoro-Jade was purchased from Millipore (Billerica, MA)
and used as a marker of degenerating neurons as pre-
viously described.27 Briefly, sections were mounted on
slides and dried overnight at room temperature. Sections
were then sequentially immersed in 100% ethanol for 5
minutes, 70% ethanol for 2 minutes, and then rinsed in
deionized water for 2 additional minutes. Sections were
then immersed in 0.06% KMnO4 while shaking for 10
minutes and then rinsed in water for 2 minutes. At that
point, the sections were incubated for 20 minutes with
gentle shaking in the Fluoro-Jade working solution (4 mL
of 0.01% stock solution of Fluoro-Jade  96 mL of 0.1%
acetic acid vehicle). The final concentration of Fluoro-
Jade was 0.0004%. After staining, the sections were
rinsed three times in water, dried at 37°C, and then cov-
ered with coverslips. To quantify the number of Fluoro-
Jade–positive cells, staining was conducted on every
10th section to cover the entire brain. Three pseudo-
random pictures for each section were taken at a 20
magnification, and the number of Fluoro-Jade–positive
cells was counted.
Statistical Analyses
We have previously reported detailed statistical analy-
ses.28 Briefly, data were analyzed using one-way and
two-way analysis of variance via GraphPad Prism (La
Jolla, CA). Post hoc Bonferroni test was then used to
s of the
variance
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dent’s t-test was used when suitable.
Results
Generation of Transgenic Mice Expressing a
25-kDa Fragment of TDP-43
In FTLD-TDP, pathological TDP-43 is hyperphosphory-
lated, ubiquitinated, and cleaved in a caspase-depen-
dent manner to generate C-terminal fragments.7,12,29 In-
terestingly, the accumulation of a 25-kDa C-terminal
fragment of TDP-43 (herein referred to as TDP-25) is
restricted to affected brain regions,7,12 suggesting that
this TDP-43 C-terminal fragment may be directly involved
in disease pathogenesis. To assess the role of TDP-25 in
the pathogenesis of FTLD-TDP, we cloned the sequence
encoding the last 199 amino acids of TDP-43 (Entrez
accession number NP_031401) in the Thy1.2 expression
cassette (Figure 1A), which includes the Thy1 mRNA
polyadenylation sequence.30 An ATG starting codon and
a Kozak sequence were also added at the 5= end of the
sequence. For the generation of transgenic mice, the
Thy1.2-TDP25 construct was injected into oocytes iso-
lated from pure C57BL/6 mice, and six founders were
identified. Initial expression analysis in the brains of
2-month-old transgenic mice using Western blot experi-
Figure 1. Generation of the TgTDP-25 mice. A: Schematic representation of
sequence is shown with exons depicted as boxes, and noncoding sequences
The expression cassette includes the Thy1.2 mRNA polyadenylation sequenc
from the brains of 2-month-old TgTDP-25 mice (lines B, C, and F) and N
arrowhead points to the endogenous, full-length TDP-43. E: Real-time PCR e
2 and 6 months of age. F: The graph shows a standard curve generated by
added to NonTg mouse DNA. The Ct values of the founders DNA was then p
and quantitative analyses of proteins extracted from the indicated tissues. I
from different brain regions of TgTDP-25(B) mice (n  4). Brn, brain; Cb, c
liver; Msc, muscle; Ob, olfactory bulb, Sc, spinal cord; SP, spinal cord; Spl, sple
from ProteinTech. -Actin was used as a loading control, and quantification
Data are presented as means  SEM and analyzed by one-way analysis ofments indicated that three lines expressed the transgene(Figure 1, B and D). Line B and F, herein referred to as
TgTDP-25(B) and TgTDP-25(F), were identified as high-
and low-expression lines, respectively, and backcrossed
to C57BL/6 wild-type mice for further analyses. Notably,
the steady-state levels of full-length TDP-43 were similar
between transgenic and nontransgenic (NonTg) litter-
mate control mice (Figure 1, B and C). Furthermore, ex-
pression analysis by real-time PCR shows that the ex-
pression levels of the transgene were similar between 2
and 6 months of age in both transgenic lines (Figure 1E).
To estimate the transgene copy number in these two
founder lines, we amplified the transgenes by real-time
PCR (n  5/line) and compared the threshold cycle (Ct)
of the founder DNA to a standard curve generated from
NonTg mouse DNA spiked with 0 to 10 copies per cell
equivalent of the transgene (see Materials and Methods).
We found that the TgTDP-25(B) and TgTDP-25(F) mice
had 4.71 0.09 and 1.21 0.16 copies of the transgene,
respectively (Figure 1F).
The Thy1.2 promoter is widely used to achieve neuro-
nal-specific expression (eg, Oddo et al23 and Caroni30).
Protein extracts in low-salt buffer from multiple tissues of
the TgTDP-25(B) line were analyzed by Western blot us-
ing an anti–TDP-43 polyclonal antibody. We found that
TDP-25 was expressed predominantly, if not exclusively,
in the central nervous system (Figure 1, G and H). To
determine in which regions of the central nervous system
truct used to generate the TgTDP-25 mice. The entire mouse Thy1.2 genomic
lines. TDP-25 (gray box) was cloned into exon 3 of the murine Thy1.2 gene.
Representative Western blots and quantitative analyses of proteins extracted
ice using the low-salt buffer. The arrow points to the transgene, and the
ents indicated that the mRNA levels of the transgene did not change between
PCR by measuring the Ct values of known copy numbers of the transgene
to the standard curve (dotted lines). G and H: Representative Western blots
epresentative Western blots and quantitative analyses of proteins extracted
m; Cx, cortex; Hp, hippocampus; Hrt, heart; Kdn, kidneys; Lng, lungs; Lvr,
ts in panels B, G, and Iwere probed with an anti–TDP-43 polyclonal antibody
Western blots were done by normalizing the protein of interest to -actin.
.the cons
as thin
e. B–D:
onTg m
xperim
real-time
lotted in
and J: R
erebellu
en. Blothe transgene was expressed, we microdissected and
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of TgTDP-25(B) and TgTDP-25(F) mice (n  6/genotype)
and measured the transgene levels by Western blot using
a polyclonal anti–TDP-43 antibody. We found that in both
lines, TDP-25 was mainly expressed in the cortex and
hippocampus (Figure 1, I and J). Additionally, the trans-
gene was expressed in cerebellum and spinal cord, with
very little expression present in the olfactory bulb (Figure
1, I and J).
TgTDP-25 Mice Develop Cognitive Deficits
Accumulation of TDP-25 is an invariable feature of FTLD-
TDP, and several in vitro studies have shown that the
expression of this fragment is toxic.7,10–15 To determine
whether expression of TDP-25 is sufficient to cause be-
havioral alterations, we tested 2- and 6-month-old
TgTDP-25 mice from both the B and F lines (n  14/
genotype/time point) in a series of cognitive and noncog-
nitive behavioral tasks. FTLD presents overlapping clini-
cal and neuropathological features with ALS and other
motor-neuron disorders.9 We thus used the open-field
activity test to measure general motor function. We found
that the spontaneous activity and gross motor function of
2- and 6-month-old TgTDP-25(B) and TgTDP-25(F) mice
were similar to NonTg mice, as assessed by the distance
traveled in the activity chamber and the average speed
during the test (Figure 2, A and B, respectively; P 0.05).
We next assessed anxiety and stress by measuring
open-field thigmotaxis and the time spent in the center of
the arena. As expected, mice spent more time in the
periphery compared to the center of the arena. This re-
sponse was independent of age or genotype as no sta-
tistically significant differences were found across the
three different genotypes at any of the ages analyzed
(Figure 2, C and D). Additionally, we did not find any
significant difference between NonTg and TgTDP-25
mice at both ages analyzed; however, a clear trend was
observed in 6-month-old mice, where mice of both trans-
genic lines spent more time in the center of the arena
compared to NonTg mice (Figure 2D). To further eluci-
date motor function in the TgTDP-25 mice, we tested the
mice using the rotarod, which is widely used to assess
motor coordination. Mice were trained for 90 seconds (six
trials/day for 3 days) on a rod at a constant speed of 15
rpm. Six 90-second probe trials were conducted on day
4 on an accelerating rod (1 rpm/second). We found that
the TgTDP-25 mice were able to stay on the rod as long
as the NonTg mice, and no statistically significant differ-
ences were observed at the ages analyzed (Figure 2E;
P 0.05). Taken together, these data indicate that 2- and
6-month-old TgTDP-25 mice do not show any detectable
motor dysfunction.
Executive function, which is controlled by the frontal
cortex, is altered in FTLD patients (eg, Ref. 31). More-
over, cognitive functions controlled by other cortical re-
gions in the temporal lobe are also impaired in FTLD
cases.32 These cognitive alterations are consistent with
the neuropathological observations showing predomi-
nant brain atrophy in frontal and temporal lobes.33 To
assess working memory in the TgTDP-25 mice, we usedthe T-maze, which relies on the tendency of mice to
alternate free choices in a T-maze during successive
trials.34 This task is dependent on several brain regions,
Figure 2. The TgTDP-25 mice develop cognitive deficits. Behavioral testing was
conducted in 2- and 6-month-oldNonTg, TgTDP-25(B) andTgTDP-25(F)mice (n
14/genotype/time point). A–D: The open-field activity test was conducted to mea-
sure spontaneous activity and anxiety. No statistically significant differences were
found among the three groups (at any of the ages analyzed) in the distance covered
during the exploration time (A) or the speed of exploration (B), indicating that gross
motor function was intact in both lines of TgTDP-25 mice. Also, no differences
among the groupswere foundwhenmeasuring the time spent in the periphery and
center of the arena (C and D, respectively), indicating that the TgTDP-25 mice had
no detectable anxiety defects. E: To measure motor coordination, we used the
accelerating rotarod and found no statistically significant changes among the three
groups analyzed. F: T-maze data show that at 2 months of age, working memory
was similar among the three groups of mice. In contrast, 6-month-old TgTDP-
25(B) mice performed significantly worse compared to NonTg and TgTDP-25(F)
mice. G: Novel object recognition tests, a behavioral task highly dependent on
the cortex, show that at 2 months of age all three groups of mice performed
similarly to each other. At 6 months of age, however, both lines of TDP-25
transgenic mice were significantly impaired compared to NonTg mice as they
spent less time exploring the new object compared to the NonTg mice. *P 
0.01, **P 0.001. Data are presented as means SEM, and each time point was
independently analyzed by one-way analysis of variance.including the basal forebrain, hippocampus, and prefron-
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similar among the three groups of mice (Figure 2F; P 
0.05). In contrast, 6-month-old TgTDP-25(B) mice per-
formed at a chance level, making the correct choice in only
57.5%  5.7% of the trials (Figure 2F). A one-way analysis
of variance indicated a significant genotype effect for this
task (P  0.05). A Bonferroni post hoc analysis indicated
that the TgTDP-25(B) mice were significantly different com-
pared to NonTg and TgTDP-25(F) mice. In contrast, TgTDP-
25(F) mice (the low-expressing line) performed as well as
NonTg mice (Figure 2F; P  0.05).
The novel object recognition task was used to measure
cortical and hippocampal function by observing sponta-
neous mouse behavior to explore a novel object.35 Dur-
ing training, mice were exposed to two objects, object A
and object B, and were left free to explore for 5 minutes.
As expected, mice spent the same amount of time ex-
ploring the two objects at all ages analyzed. Indeed, at 2
months of age, the NonTg and TgTDP-25(B) mice spent
47.5%  3.2% and 49.5%  2.4%, respectively, explor-
ing object A. Similarly, at 6 months of age, the NonTg and
TgTDP-25(B) mice spent 51.5%  1.8% and 49.4%S 
1.4%, respectively, exploring object A. During the probe
trials, object B was replaced with a new object. At 2
months of age, all three groups showed a clear prefer-
ence for the novel object, and no statistical differences
were detected between transgenic and NonTg mice (Fig-
ure 2G; P  0.05). At 6 months of age, the NonTg mice
spent 72.1%  1% of their time exploring the new object.
In contrast, the TgTDP-25(B) mice did not discriminate
between the novel and old object and performed at a
chance level, spending 51.3%  3.3% of their time ex-
ploring the new object (Figure 2G). The TgTDP-25(F)
mice performed better than the TgTDP-25(B) mice, but
not as well as the NonTg mice, because they spent
59.8%  3.1% of their time exploring the new object
(Figure 2G). One-way analysis of variance indicated a
significant genotype effect for this task (P  0.0001). A
Bonferroni post hoc analysis indicated that the TgTDP-
25(B) and TgTDP-25(F) mice were significantly impaired
compared to NonTg mice (P  0.001 and P  0.01,
respectively). The difference between TgTDP-25(B) and
TgTDP-25(F) mice did not reach statistical significance
(P  0.05). Taken together, these data indicate that al-
though the TgTDP-25 mice have no gross alterations in
motor function, they develop cognitive dysfunctions in
two independent tasks. Furthermore, deficits in the object
recognition in both transgenic lines clearly indicate that
the cognitive impairments in the TgTDP-25 mice are not
simply due to an effect of integration of the transgene.
Increased Soluble TDP-25 Levels in
6-Month-Old Transgenic Mice
In TDP-43 proteinopathies, the solubility of TDP-43 and its
C-terminal fragments is altered, leading to the formation
of insoluble aggregates.7 We next wanted to determine
the molecular and biochemical bases of the onset of
cognitive deficits in the TgTDP-25 mice. We first ex-
tracted proteins from the brains of 2- and 6-month-oldTgTDP-25(B) and TgTDP-25(F) and NonTg mice with buf-
fers of increasing strength and analyzed the samples by
Western blot. Although the steady-state levels of full-
length TDP-43 in the low- and high-salt fractions did not
change between 2 and 6 months of age (Figure 3, A-C),
we found a significant increase in TDP-25 levels in the
low-salt fraction from the brains of the TgTDP-25(B) and
TgTDP-25(F) mice (Figure 3, A and D). We also found that
the levels of TDP-25 in different fractions change be-
tween 2 and 6 months of age. Indeed, we could only
detect a faint 25-kDa band in the high-salt fraction from
the brains of 2-month-old TgTDP-25(B) mice, whereas in
the TgTDP-25(F) low-expressing line, TDP-25 was not
detectable at this age (Figure 3A). In contrast, as the
mice aged, we found a marked and significant increase
in TDP-25 levels in both transgenic lines (Figure 3, A and
E). TDP-43 C-terminal fragments were below detection
levels in the sarkosyl and urea fractions. Together these
Figure 3. Increased soluble TDP-25 levels in 6-month-old TgTDP-25 mice.
A: Representative Western blots of proteins extracted from the brains of 2-
and 6-month-old transgenic and NonTg mice, in low- and high-salt buffers.
Blots were probed with an anti–TDP-43 polyclonal antibody from Protein-
Tech. Two different exposure times are presented to show the less abundant,
low molecular weight bands. B: Quantitative analyses of the blots from
low-salt extraction show that the levels of full-length TDP-43 were similar
between the TgTDP-25(B) and TgTDP-25(F) mice and did not change as a
function of age. C: In contrast, we found the steady-state levels of TDP-25
(arrow) significantly increased as a function of age in both the TgTDP-25(B)
and TgTDP-25(F) mice. D: Quantitative analyses of the blots from high-salt
extracts show that the levels of full-length TDP-43 were similar between the
TgTDP-25(B) and TgTDP-25(F) mice and did not change as a function of age.
E: TDP-25 levels increased as a function of age in the high-salt fraction in
both TgTDP-25 lines, suggesting a change in aggregation of this fragment as
a function of age. n  6/genotype/age. *P  0.05, **P  0.01. -Actin was
used as a loading control, and quantifications of the Western blots were done
by normalizing the protein of interest to -actin. Data are presented as
means  SEM and analyzed by two-way analysis of variance, with genotype
and age as independent variables.data suggest that soluble steady-state levels of TDP-25
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sistent with other reports.17
In FTLD-TDP, TDP-43 undergoes several post-trans-
lational modifications, including phosphorylation and
ubiquitination.7 We thus sought to determine whether
the expression of TDP-25 was sufficient to cause phos-
phorylation and ubiquitination of endogenous TDP-43.
Toward this end, sections from 6-month-old TgTDP-25(B)
and age-matched NonTg mice (n  6/genotype) were
stained with a TDP-43 antibody that selectively recog-
nizes TDP-43 when phosphorylated at S409/410. Only
background staining was found in both groups of mice
(Figure 4A). Additionally, we found that at 6 months of
age, TgTDP-25(B) mice were devoid of ubiquitin-positive
TDP-43 inclusions (Figure 4B), which is consistent with
the lack of TDP-43 C-terminal fragments in the sarkosyl
and urea fractions. To determine whether the expression
of TDP-25 was sufficient to cause neurodegeneration, we
stained sections from 6-month-old TgTDP-25(B) and age-
matched NonTg mice (n 6/genotype) with Fluoro-Jade,
a dye known to label degenerating neurons.27 The num-
ber of Fluoro-Jade–positive cells was very scarce for both
groups of mice (Figure 4C), and quantitative analysis
showed no statistically significant difference between the
two genotypes (Figure 4D).
It is well established that in FTLD-TDP, TDP-43 is mis-
localized from its nuclear location to the cytosol.7 Further-
more, in vitro studies show that the expression of C-ter-
minal fragments of TDP-43 leads to a mislocalization of
endogenous full-length TDP-43, even though the litera-
ture does not show general agreement.10,12–15 To bio-
chemically study the intracellular localization of TDP-43
and its C-terminal fragments, we extracted nuclear and
cytosolic fractions from 2- and 6-month-old TgTDP-25(B)
and NonTg mice (Figure 5A). As expected, most of the
full-length TDP-43 was in the nuclear fraction at both
ages (Figure 5, A and B); additionally, at 2 and 6 months
of age, the levels of full-length TDP-43 were similar be-
tween TgTDP-25(B) and NonTg mice (Figure 5, A and B).
Notably, in the cytosolic and nuclear fractions of 6-month-
old mice, we found a series of TDP-43 fragments in both
TgTDP-25(B) and NonTg mice that were not present at 2
months of age (Figure 5A). In the cytosolic fraction, we
found an 25-kDa band, which was exclusively present
in the TgTDP-25(B) mice (Figure 5, A and D) and most
likely corresponds to the TDP-25 transgene. In the nu-clear fraction, we found a triplet of fragments of similar
molecular weight that were significantly higher in the
TgTDP-25(B) mice compared to the NonTg mice (Figure
5, A and D). Notably, the higher molecular weight band of
this triplet was present only in the TgTDP-25(B) mice and
most likely represents the TDP-25 transgene. The other
two bands are also present in the NonTg mice, although
the levels are significantly lower than those of the TgTDP-
25(B) mice, and thus they may represent different frag-
ments of endogenous TDP-43 and not the transgene.
Additionally, we found another triplet of bands of 35
kDa (Figure 5A). Surprisingly, these fragments were sig-
nificantly higher in the NonTg mice compared to the
TgTDP-25(B) mice (Figure 5, A and C), suggesting that
these are derived from a normal processing of TDP-43.
Thus, it is tempting to speculate that the expression
of TDP-25 is altering the processing of full-length, endog-
enous TDP-43, leading from a process that mainly gen-
erates 39-kDa fragments in the NonTg mice to one that
mainly forms 25-kDa fragments in the TgTDP-25(B)
mice. As expected, in the cytosolic fraction, we found that
the levels of the TDP-25 were significantly higher in
6-month-old TgTDP-25(B) mice compared to age-
matched NonTg mice (Figure 5, A and D). Additionally, in
the cytosolic fraction, we found a robust and significant
accumulation of a 35-kDa fragment in the TgTDP-25(B)
mice (Figure 5, A and C), further suggesting that the
expression of the transgene has altered the normal pro-
cessing of endogenous, full-length TDP-43.
Discussion
Neuropathologically, TDP-43 has been linked to FTLD-
TDP; indeed, TDP-43 has been identified as the major
component of ubiquitin-positive inclusions that character-
ize FTLD-TDP.7 Genetically, mutations in TDP-43 lead to
ALS,8 a neurodegenerative disorder with clinical and
neuropathological features overlapping with FTLD.9 Path-
ological TDP-43 is cleaved to form TDP-25, a C-terminal
fragment of TDP-43 that consistently has been isolated in
human cases of FTLD-TDP and ALS.7 Furthermore, we
and others have previously shown that the expression of
TDP-25 in vitro is toxic and recapitulates key pathological
features of TDP-proteinopathies.10,12–15 Here, we report
Figure 4. Absence of ubiquitin-positive inclusions
and cell death in TgTDP-25 mice. A: Representative
hippocampal sections from 6-month-old NonTg and
TgTDP-25(B) mice stained with a phospho-specific
TDP-43 antibody (n  6/genotype). B: Cortical sec-
tions from 6-month-old TgTDP-25(B) mice were
double stained with a C-terminal anti-TDP-43 anti-
body and with an anti-ubiquitin antibody. The over-
lay shows that at this age, the TgTDP-25(B) mice
have no ubiquitin-positive TDP-43 inclusions. C:
Representative cortical and hippocampal sections
from 6-month-old NonTg and TgTDP-25(B) mice
stained with Fluoro-Jade. D: Quantitative analysis of
the Fluoro-Jade–positive cells, conducted as de-
scribed in Materials and Methods, showed no statis-
tically significant difference between the two groups
of mice (n  6/genotype). Data are presented as
means  SEM and analyzed by Student’s t-test.the significant finding that expression of TDP-25 in vivo is
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highlighting new mechanistic insights into the pathogen-
esis of TDP-43 proteinopathies, including FTLD-TDP and
ALS. Indeed, these two disorders may share similar
pathogenic mechanisms because the biochemical profile
of TDP-43 is consistent between ALS and FTLD-TDP.
Pathological TDP-43 is mislocalized from its physiolog-
ical nuclear location to the cytoplasm, where it forms
ubiquitin-positive inclusions.7 Thus, it is not clear whether
the primary culprit in the disease pathogenesis is the
accumulation of ubiquitin-positive TDP-43 inclusions
(through a gain-of-function mechanism) or the depletion
of nuclear TDP-43 (through a loss-of-function mecha-
nism). The data reported here indicate that neither inclu-
sions nor nuclear depletions are necessary for the onset
Figure 5. TDP-25 expression leads to altered processing of full-length en-
dogenous TDP-43. A: Representative Western blots extracted from 2- and
6-month-old TgTDP-25 and NonTg mice. Different exposures are presented
to show the less abundant, low molecular TDP-43 fragments. Proteins were
extracted from the cytosolic and nuclear fraction, as depicted in the figure.
TDP-43 blots were probed with an anti-TDP-43 polyclonal antibody from
ProteinTech. -Actin and LaminA were used as loading controls for the
cytosolic and nuclear fractions, respectively. B: As expected, quantitation of
the full-length TDP-43 band (panel A, top right blot, black arrow), shows
that the levels of TDP-43 are significantly higher in the nucleus compared to
the cytoplasm in both transgenic and NonTg mice. Additionally, the levels of
TDP-43 were not different in the cytosolic or nuclear fractions between
TgTDP-25(B) and NonTg mice. C: Quantitative analysis of the three bands of
39-kDa (panel A, top right blot, white arrow). Notably, these bands
were not present in 2-month-old mice, irrespective of the genotype. In the
nuclear fraction of 6-month-old mice, the levels of these fragments were
significantly higher in NonTg mice compared to TgTDP-25(B) mice. In the
TgTDP-25(B) mice, however, there was a striking increase of an 35-kDa
band in the cytosolic fraction compared to NonTg mice, suggesting that in the
TgTDP-25(B) mice, there is a possible redistribution of the 35-kDa bands
from the nucleus (where they are more abundant in NonTg mice) to the
cytosol. D: Quantitative analysis of the 25-kDa bands (panel A, bottom
right blot, arrowhead) shows that the TDP-25 transgene is also present in
the nuclear fraction, despite the lack of putative nuclear localization signals.
*P  0.05, **P  0.01. -Actin and LaminA were used as loading controls for
cytosolic and nuclear fractions, respectively. Quantifications of the Western
blots were done by normalizing the fragment of interest to -actin of LaminA.
Data are presented as means  SEM and analyzed by two-way analysis of
variance, with genotype and age as independent variables.of behavioral alterations. Indeed, we show that the earli-est detectable cognitive deficits in the TgTDP-25(B) mice
occur at 6 months of age. Notably, at this age, the only
overt change in the brain of these mice is the increase in
soluble TDP-25 levels. In view of these data, we suggest
that the onset of cognitive deficits is due to the build-up of
soluble TDP-25 most likely through a toxic gain of func-
tion. This is a recurring event in several neurodegenera-
tive diseases. For example, strong evidence shows that
in Alzheimer’s disease, the accumulation of soluble spe-
cies of amyloid- and tau may be the primary event in the
disease pathogenesis, whereas the formation of insoluble
inclusions could represent a secondary event.36 Analysis
of TDP-43 transgenic mice expressing wild-type or mu-
tant full-length TDP-43 indicates the possibility of a rela-
tion between gene dosage and the formation of TDP-43
inclusions.17 We cannot exclude the possibility that in-
creasing TDP-25 levels in the TgTDP-25(B) mice (eg, by
generating homozygous mice) may lead to TDP-43–pos-
itive inclusions. Nevertheless, data clearly indicate that
such inclusions are not necessary for the onset of cog-
nitive deficits. However, it should be pointed out that the
data presented here are not meant to exclude the possi-
bility that TDP-43 inclusions and the nuclear depletion of
TDP-43 are toxic events for overall brain functioning. In-
deed, data generated from studies of transgenic mice
expressing full-length wild-type and mutant TDP-43 show
the toxicity of TDP-43–positive inclusions.17,19–21 Further-
more, the loss of TDP-43 is also toxic as shown by knock-
out experiments: homozygous TDP-43 knockout mice are
not vital; heterozygous mice show muscle weakness.37,38
Consistent with these results, conditional knockout mice
die within 9 days following ablation of the TDP-43 gene.39
These data, together with the data presented here, indi-
cate that the onset of behavioral deficits is due to the
increase of soluble TDP-25 levels. As the disease pro-
gresses, TDP-43 is mislocalized and accumulates in the
cytoplasm, and both the toxic gain of function, due to the
presence of such cytoplasmic inclusions, and the loss of
nuclear TDP-43 function further contribute to the progres-
sion of the disease.
The cause of neurodegeneration in TDP-43 pro-
teinopathies remains to be elucidated. Transgenic mice
and flies have been generated and recapitulate several
key features of the disease, including neurodegenera-
tion. Notably, however, because these models show
ubiquitin-positive inclusions, TDP-43 deposits, and accu-
mulation of C-terminal fragments, it has been challenging
to identify the primary cause of neurodegeneration in
TDP-43 proteinopathies. At the ages analyzed, the TDP-
25(B) mice do not show apparent neurodegeneration,
indicating that the build-up of soluble TDP-25 is not re-
quired for neurodegeneration. These data are consistent
with a recent report showing that neurodegeneration in
a transgenic mouse model expressing full-length
TDP-43 lacking the two nuclear localization signals
(NLSs) occurs independently of TDP-43 inclusions and
C-terminal fragments.18
Structurally, TDP-43 has two NLSs both localized be-
tween amino acids 82 and 98, well outside the 25-kDa
C-terminal fragment expressed by the TgTDP-25(B)
mice.40 Although in vitro experiments show that removing
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vivo TDP-43 sorting appears to be more complex. For
example, in mice expressing TDP-43 lacking both NLSs,
the transgene is found in both the cytoplasm and the
nucleus.18 Here, we show that the levels of TDP-25 are
significantly higher in the nucleus than in the cytoplasm,
despite the fact that TDP-25 lacks the NLSs. Although it
is possible that processing of endogenous TDP-43
may contribute to the high levels of nuclear TDP-25,
our data are consistent with previous work reporting
that when expressed in vitro, TDP-25 localizes to the
nucleus.10,11,13–15 Further supporting changes in TDP-43
processing and trafficking, we reported the striking find-
ing of the mislocalization of 35-kDa fragments, which in
NonTg mice are mainly present in the nuclear fraction,
whereas in TgTDP-25(B) mice, these fragments accumu-
late in the cytosolic fraction. Although the nature and
significance of these fragments remain to be elucidated,
these data indicate that the expression of the TDP-25
fragment is sufficient to alter the physiological endoge-
nous TDP-43 processing. Overall, it is evident that more
work needs to be done to understand the basic molecular
mechanisms underlying TDP-43 processing and its im-
port and export from the nucleus. Understanding such
mechanisms may be lead to a better understanding of
the disease pathogenesis.
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